Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review
Poi M, Berger M, Lustberg M, Layman R, Shapiro C, Ramaswamy B, Mrozek E, Olson E, Wesolowski R. Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review. Supportive Care In Cancer 2013, 21: 2679-2686. PMID: 23686402, PMCID: PMC3769512, DOI: 10.1007/s00520-013-1842-3.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBreast NeoplasmsDocetaxelFemaleGranulocyte Colony-Stimulating FactorHumansIncidenceMiddle AgedPaclitaxelSkin DiseasesSurvival RateTaxoidsConceptsBreast cancer patientsSkin toxicityCancer patientsCase seriesGranulocyte colony-stimulating factor supportToxicity eventsColony-stimulating factor supportDose-dense doxorubicinOperable stage IResultsThirty-four patientsSevere skin toxicityEvidence-based preventionElectronic medical recordsInstitutional review boardDermatologic toxicitiesDocetaxel 75Docetaxel monotherapyWeekly paclitaxelCyclophosphamide regimenClinical courseFactor supportMedical recordsTreatment strategiesGrade 3Inclusion criteria